Jonathan Kay, MD

Jonathan Kay, MD
 

Director of Clinical Research
Rheumatology Division
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA

How should one "sequence" therapy in patients who require biologic therapy? Is there a "one-sequence-fits-all" strategy? Can one start with any biologic agent in conjunction with methotrexate? Video

How should one "sequence" therapy in patients who require biologic therapy? Is there a "one-sequence-fits-all" strategy? Can one start with any biologic agent in conjunction with methotrexate?

How should one optimally “sequence” therapy in patients who require biologic therapy? Is there a “one-sequence-fits-all” strategy? Or can one start with any of the biologic agents as an initial therapy in conjunction with methotrexate?
Jonathan Kay, MD

Jonathan Kay, MD

Should biologically-naive patients be approached differently from patients on previous B-DMARD therapy, but have suboptimal clinical results? What is the role of IL-6 inhibitors in this population? Video

Should biologically-naive patients be approached differently from patients on previous B-DMARD therapy, but have suboptimal clinical results? What is the role of IL-6 inhibitors in this population?

Should biologically-naïve patients be approached differently from patients who have been on a previous B-DMARD therapy, but have suboptimal clinical results? What is the role of IL-6 inhibitors in this population?
Jonathan Kay, MD

Jonathan Kay, MD

Can you discuss the design and results of the TARGET trial? Video

Can you discuss the design and results of the TARGET trial?

Can you discuss the design and results of the TARGET trial?
Jonathan Kay, MD

Jonathan Kay, MD

How, why, and where should IL-6 cytokine inhibitors fit into evidence- and/or expert-based roadmaps for sequential approaches to RA management? Video

How, why, and where should IL-6 cytokine inhibitors fit into evidence- and/or expert-based roadmaps for sequential approaches to RA management?

How, why, and where should IL-6 cytokine inhibitors fit into evidence- and/or expert-based roadmaps for sequential approaches to RA management?
Jonathan Kay, MD

Jonathan Kay, MD

What are predictors of risk progression and/or poor therapeutic response in RA that would make a patient appropriate for early, aggressive therapy with biologic therapy? Video

What are predictors of risk progression and/or poor therapeutic response in RA that would make a patient appropriate for early, aggressive therapy with biologic therapy?

What are predictors of risk progression and/or poor therapeutic response in RA that would make a patient appropriate for early, aggressive therapy with biologic therapy?
Jonathan Kay, MD

Jonathan Kay, MD

Can the Simplified Disease Activity Index (SDAI) provide predictive information that guides aggressiveness of therapy for RA? Video

Can the Simplified Disease Activity Index (SDAI) provide predictive information that guides aggressiveness of therapy for RA?

Can the Simplified Disease Activity Index (SDAI) provide predictive information that guides aggressiveness of therapy for RA?
Jonathan Kay, MD

Jonathan Kay, MD

What are the major unmet needs in patients with RA? Video

What are the major unmet needs in patients with RA?

What are the major unmet needs in patients with RA?
Jonathan Kay, MD

Jonathan Kay, MD